NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

QGEN

Qiagen NV

May 21 • 04:00PM ET

42.32

Dollar change -0.38
Percentage change -0.89	%

Healthcare • Diagnostics & Research • Netherlands • NYSE

Peers: TMO DHR ILMN A BIO TECH WAT MTD HOLX BRKR

| Held by: IWR IWD IWS PBE IWB BBH DFIS IYH VONV JQUA

Scroll to Statements

Index	-	P/E	101.39	EPS (ttm)	0.42	Insider Own	0.79%	Shs Outstand	216.56M	Perf Week	2.84%
Market Cap	9.15B	Forward P/E	16.81	EPS next Y	2.52	Insider Trans	0.00%	Shs Float	214.42M	Perf Month	-0.05%
Income	93.68M	PEG	13.98	EPS next Q	0.60	Inst Own	72.11%	Short Float	2.35%	Perf Quarter	9.72%
Sales	2.00B	P/S	4.57	EPS this Y	4.37%	Inst Trans	-6.47%	Short Ratio	3.75	Perf Half Y	2.56%
Book/sh	15.74	P/B	2.69	EPS next Y	7.70%	ROA	1.65%	Short Interest	5.04M	Perf Year	-7.36%
Cash/sh	4.46	P/C	9.49	EPS next 5Y	7.25%	ROE	2.67%	52W Range	37.63 - 47.92	Perf YTD	-4.95%
Dividend Est.	0.03 (0.06%)	P/FCF	18.09	EPS past 5Y	-	ROI	1.97%	52W High	-11.69%	Beta	0.66
Dividend TTM	-	Quick Ratio	2.83	Sales past 5Y	6.09%	Gross Margin	63.48%	52W Low	12.46%	ATR (14)	0.98
Dividend Ex-Date	Jul 02, 2025	Current Ratio	3.37	EPS Y/Y TTM	-75.89%	Oper. Margin	26.06%	RSI (14)	51.95	Volatility	1.60% 1.97%
Employees	5765	Debt/Eq	0.41	Sales Y/Y TTM	3.31%	Profit Margin	4.68%	Recom	2.00	Target Price	49.43
Option/Short	Yes / Yes	LT Debt/Eq	0.40	EPS Q/Q	12.56%	Payout	0.00%	Rel Volume	1.28	Prev Close	42.70
Sales Surprise	3.11%	EPS Surprise	9.45%	Sales Q/Q	5.37%	Earnings	May 07 AMC	Avg Volume	1.35M	Price	42.32
SMA20	-0.29%	SMA50	2.95%	SMA200	-1.70%	Trades		Volume	1,718,495	Change	-0.89%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-04-25	Downgrade	Redburn Atlantic	Buy → Neutral
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral	$52 → $42
Jan-06-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$48
Dec-10-24	Upgrade	Jefferies	Hold → Buy	$42.50 → $54
Oct-17-24	Downgrade	HSBC Securities	Buy → Hold	$49
Jun-27-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$50
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$44
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Dec-07-23	Upgrade	Goldman	Neutral → Buy	$50
Sep-12-23	Initiated	Robert W. Baird	Outperform	$50
May-23-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-18-22	Initiated	Morgan Stanley	Equal-Weight
Jan-18-22	Upgrade	DZ Bank	Hold → Buy
Oct-15-21	Resumed	Cowen	Market Perform	$55
Oct-14-21	Initiated	Redburn	Buy
Jul-14-21	Downgrade	Kepler	Buy → Hold	$49.53
Jun-03-21	Initiated	Goldman	Neutral	$52
Oct-06-20	Resumed	BofA Securities	Buy	$59
Sep-28-20	Upgrade	Kepler	Hold → Buy
Aug-24-20	Upgrade	Citigroup	Neutral → Buy	$48 → $62

Show Previous Ratings

May-19-25 09:45AM	Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
May-16-25 09:50AM	Here's Why Qiagen (QGEN) is a Strong Momentum Stock (Zacks)
May-15-25 09:40AM	Here's Why Qiagen (QGEN) is a Strong Value Stock (Zacks)
May-13-25 07:07AM	QIAGEN Stock Gains Following the Acquisition of Genoox (Zacks)
May-12-25 04:05PM	QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software (Business Wire)
09:37AM	Loading…
May-08-25 09:37AM	Analyst Report: Qiagen N.V. (Morningstar Research)
06:52AM	QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up (Zacks)
May-07-25 07:30PM	Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings (Zacks)
06:15PM	Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates (Zacks)
05:10PM	Qiagen: Q1 Earnings Snapshot (Associated Press Finance)
04:20PM	QIAGEN announces plans for transition in leadership of Supervisory Board (Business Wire)
04:05PM	QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase (Business Wire)
09:36AM	Qiagen NV (QGEN) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
08:45AM	QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting (Business Wire)
May-06-25 09:15AM	Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics (Zacks)
11:40AM	Loading…
May-02-25 11:40AM	QGEN or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
May-01-25 05:35PM	Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
10:01AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-25 10:01AM	Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-29-25 04:05PM	QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control (Business Wire)
09:40AM	Why Qiagen (QGEN) is a Top Value Stock for the Long-Term (Zacks)
Apr-22-25 04:05PM	QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025 (Business Wire)
Apr-16-25 09:50AM	Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term (Zacks)
Apr-15-25 01:30AM	QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation (Business Wire)
Apr-10-25 01:31PM	Analyst Report: Qiagen N.V. (Morningstar Research)
09:53AM	Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock? (Zacks)
Apr-08-25 11:22AM	QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast (Business Wire)
Apr-07-25 09:28AM	Analyst Report: Qiagen N.V. (Morningstar Research) +5.36%
Apr-06-25 02:28PM	QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook (Business Wire)
Apr-01-25 01:30AM	QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts (Business Wire)
10:00AM	Loading…
Mar-31-25 10:00AM	Bio-Techne Opens New Customer Experience Centre in Germany (Zacks)
06:00AM	QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results (Business Wire)
Mar-19-25 09:57AM	HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip? (Zacks)
Mar-07-25 11:31AM	Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound? (Zacks)
07:31AM	FDA clears Qiagens QIAstat-Dx Gastrointestinal Panel 2 Mini B (Medical Device Network)
Mar-06-25 01:00AM	QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio (Business Wire)
Mar-03-25 06:48PM	Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
01:00AM	QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing (Business Wire)
Feb-23-25 07:00AM	2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62% (Motley Fool)
Feb-13-25 04:05PM	QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region (Business Wire)
Feb-06-25 11:22AM	Analyst Report: Qiagen N.V. (Morningstar Research)
Feb-05-25 06:00PM	Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Qiagen (QGEN) Q4 Earnings Lag Estimates (Zacks)
04:59PM	Qiagen: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	QIAGEN delivers solid Q4 2024 growth ahead of outlook (Business Wire)
07:06AM	Qiagen NV (QGEN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-04-25 04:05PM	QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent (Business Wire)
07:05AM	Qiagen NV (QGEN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Jan-29-25 10:00AM	Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-16-25 04:05PM	QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million (Business Wire)
Jan-15-25 08:13AM	QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast (Business Wire)
Jan-12-25 01:05PM	QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase (Business Wire)
Jan-10-25 07:40AM	Qiagen scoops FDA clearance for gastrointestinal panel (Medical Device Network)
01:30AM	QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples (Business Wire)
Jan-09-25 04:05PM	QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care (Business Wire)
12:10PM	Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-07-25 04:05PM	QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content (Business Wire)
Dec-30-24 03:45PM	Why Is Qiagen N.V. (QGEN) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
09:50AM	Here's Why Qiagen (QGEN) is a Strong Momentum Stock (Zacks)
Dec-13-24 09:50AM	Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-12-24 04:05PM	QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data (Business Wire)
Dec-06-24 11:31AM	Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-05-24 04:05PM	QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation (Business Wire)
Nov-29-24 09:40AM	Here's Why Qiagen (QGEN) is a Strong Value Stock (Zacks)
05:09AM	QIAGEN announces new site in Barcelona for QIAstat-Dx operations (Medical Device Network)
Nov-28-24 10:51AM	QIAGEN introduces new custom tools for microbial analysis (Medical Device Network)
06:00AM	QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing (Business Wire)
Nov-27-24 04:05PM	QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis (GlobeNewswire)
Nov-25-24 09:50AM	Here's Why Qiagen (QGEN) is a Strong Momentum Stock (Zacks)
Nov-12-24 04:05PM	QIAGEN collaborates with McGill University to advance microbiome research (GlobeNewswire)
Nov-11-24 09:15AM	Don't Overlook Qiagen (QGEN) International Revenue Trends While Assessing the Stock (Zacks)
Nov-09-24 06:35AM	Qiagens Financial Growth and Rising Debt in Q3 2024 (TipRanks)
Nov-08-24 09:40AM	Why Qiagen (QGEN) is a Top Value Stock for the Long-Term (Zacks)
02:19AM	Qiagen NV (QGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 11:19AM	Analyst Report: Qiagen N.V. (Morningstar Research)
Nov-06-24 08:30PM	Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics (Zacks)
06:40PM	Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates (Zacks)
05:54PM	Qiagen: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	QIAGEN delivers solid Q3 2024 growth ahead of outlook, increases full-year 2024 adjusted EPS outlook (GlobeNewswire)
07:04AM	Qiagen NV (QGEN) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-05-24 07:37AM	Qiagen NV (QGEN) Q3 2024 Earnings Report Preview: What to Expect (GuruFocus.com)
Nov-04-24 09:16AM	Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
01:30AM	QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics (GlobeNewswire)
Oct-29-24 02:30AM	QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment (GlobeNewswire)
Oct-10-24 04:05PM	QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications (GlobeNewswire)
07:41AM	QIAGEN N.V. to release results for Q3 2024 and hold webcast (GlobeNewswire)
Oct-07-24 04:05PM	Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer (GlobeNewswire)
Oct-01-24 08:45AM	Neogen Announces the Appointment of New Board Member (PR Newswire)
Sep-30-24 04:05PM	QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology (GlobeNewswire)
Sep-27-24 09:53AM	Qiagen secures EU IVDR certification for QIAstat-Dx systems and panels (Medical Device Network)
08:32AM	Qiagens QIAstat-Dx respiratory diagnostic wins FDA clearance (Medical Device Network)
Sep-26-24 04:05PM	QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays (GlobeNewswire)
06:12AM	PreAnalytiX introduces urine liquid biopsy solution (Medical Device Network)
Sep-25-24 04:05PM	PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples (GlobeNewswire)
Sep-23-24 04:05PM	QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database (GlobeNewswire)
Sep-18-24 04:05PM	QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform (GlobeNewswire)
Sep-12-24 04:05PM	QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs (GlobeNewswire)
Sep-05-24 09:13AM	Qiagen and Lilly team up for Alzheimers genotype test (Medical Device Network)
Sep-04-24 04:05PM	QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer's disease (GlobeNewswire)
Sep-03-24 05:05PM	QIAGEN N.V. announces conversion price of new net share settled convertible bonds (GlobeNewswire)

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sackers Roland	Officer	Sep 11 '24	Proposed Sale	46.00	25,000	1,150,000		Sep 11 06:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QGEN

Qiagen NV

Upgrade your FINVIZ experience